<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="31730" whole_study_id="31730" phs="001863" v="1" p="1" createDate="2018-10-12T12:29:24-05:00" completedByGPADate="2018-10-30T11:04:23-05:00" modDate="2022-02-01T22:05:14-05:00" maxParentChildStudyModDate="2022-02-01T22:05:14-05:00" handle="CALGB_40603" num_participants="443"><StudyInfo accession="phs001863.v1.p1" parentAccession="phs001863.v1.p1"><BioProject id="PRJNA553269" entrez_id="553269" type="bp_admin_access"/><BioProject id="PRJNA553270" entrez_id="553270" type="bp_data_submission"/><StudyNameEntrez>CALGB 40603: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/><StudyType22 name="whole_targ_exome"/><StudyType22 name="rnaseq_whole_targ_transcriptome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="germline"/><StudyType22 name="dna"/><StudyType22 name="rna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>germline</StudyType><StudyType>dna</StudyType><StudyType>rna</StudyType><StudyType>targeted_exome</StudyType><StudyType>whole_transcriptome</StudyType><StudyType>rna_seq_derived_expression</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages/></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="WMSIKOV" aid="2" auth="eRA" login="WMSIKOV" fname="William" mname="" lname="Sikov" email="WSikov@wihri.org"><Role allow_direct_access="true">PI</Role><Organization>BROWN UNIVERSITYWOMEN AND INFANTS HOSPITAL-RHODE ISLAND</Organization></Person><Person nedid="0011263528" aid="1" auth="cit" login="mooneym" fname="Margaret" mname="Marian" lname="Mooney" email="mm723k@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person nedid="PASPEARS" aid="2" auth="eRA" login="PASPEARS" fname="Patricia" mname="" lname="Spears" email="paspears@med.unc.edu"><Role>PI_ASSIST</Role><Organization>UNIV OF NORTH CAROLINA CHAPEL HILLDUKE UNIVERSITY</Organization></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011552437" aid="1" auth="cit" login="jawang" fname="Zhen" mname="Yuan" lname="Wang" email="zhen.wang@nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>The Alliance for Clinical Trials in Oncology NIH-NCI grants U10CA031946; U10CA180821. The Statistics and Data Center grants U10CA033601; U10CA180882. The Alliance Biorepository and Biospecimen Resource grant U24CA196171   Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. PMID:25092775</acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=31900&amp;file=get&amp;page=file" filename="CALGB 40603 NCI DUC.docx" md5="1195a830f2bcf4cce7d5b8113675f26e" size="57231" modDate="2018-10-17T13:53:31-05:00" content-type="application/vnd.openxmlformats-officedocument.word"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=31911&amp;file=get&amp;page=file" filename="CALGB 40603 NCI DUC.docx.pdf" md5="daeca34d3d8dddb5caff458402a58f1e" size="1039265" modDate="2018-10-18T09:18:51-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="3268" CGType="cg_class_DS" title="Disease-Specific (Cancer, COL)" name="DS-CA-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of the data must be related to Cancer.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to the NCICTEPpubs@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPpubs@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>